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Abstract
Epithelial–mesenchymal transition (EMT) plays a critical role in the early stages of dissemination
of carcinoma leading to metastatic tumors, which are responsible for over 90% of all cancer-
related deaths. Current therapeutic regimens, however, have been ineffective in the cure of
metastatic cancer, thus an urgent need exists to revisit existing protocols and to improve the
efficacy of newly developed therapeutics. Strategies based on preventing EMT could potentially
contribute to improving the outcome of advanced stage cancers. To achieve this goal new assays
are needed to identify targeted drugs capable of interfering with EMT or to revert the
mesenchymal-like phenotype of carcinoma to an epithelial-like state. Current assays are limited to
examining the dispersion of carcinoma cells in isolation in conventional 2-dimensional (2D)
microwell systems, an approach that fails to account for the 3-dimensional (3D) environment of
the tumor or the essential interactions that occur with other nearby cell types in the tumor
microenvironment. Here we present a microfluidic system that integrates tumor cell spheroids in a
3D hydrogel scaffold, in close co-culture with an endothelial monolayer. Drug candidates
inhibiting receptor activation or signal transduction pathways implicated in EMT have been tested
using dispersion of A549 lung adenocarcinoma cell spheroids as a metric of effectiveness. We
demonstrate significant differences in response to drugs between 2D and 3D, and between
monoculture and co-culture.
Keywords




Integr Biol (Camb). Author manuscript; available in PMC 2014 May 30.
Published in final edited form as:














Metastasis, the final stage of tumor progression, is responsible for the deaths of most cancer
patients.1 Yet, there are very few drugs currently available that interfere with the advanced
stages of the disease.2 A majority of cancers are of epithelial origin, and the progression of
carcinoma has been hypothesized to involve epithelial-mesenchymal transition (EMT).3
EMT has also been implicated in the formation of tumor-initiating or cancer stem cells and
in drug resistance.4, 5 These studies prompt the development of new strategies for anti-
metastatic drugs based on the concept of inhibiting EMT.6
Multiple signaling pathways have been associated with EMT of carcinoma cells including
activation of tyrosine kinase surface receptors such as epidermal growth factor receptor
(EGFR), transforming growth factor-β receptor 1 (TGF-βR1) and hepatocyte growth factor
receptor (HGFR/c-Met). Numerous cytokines, extracellular matrix components and matrix
metalloproteases also play a major role in EMT.7–10 Some of these pathways may act in
concert through reciprocal interaction between stromal and carcinoma cells to induce
EMT.11 Carcinoma cells with decreased cell-cell adhesion can delaminate from the primary
tumor to invade the adjacent stroma and intravasate into blood and lymph vessels. These
phenotypic changes, in part driven by transcriptional controls,12, 13 can be observed in
culture within a reasonably short period of time (2–3 d). In vitro assays used to screen for
anti-metastatic compounds should replicate the local tumor microenvironment to the extent
possible, including a microvasculature, growth factors and ECM, in order to better mimic
the mechanisms driving tumor progression. Based on this reasoning, in vitro drug screening
in a more realistic setting in the presence of other interacting cell populations has the
potential to accelerate the search for effective drugs that can inhibit the initiation of EMT,
with minimal toxicity to normal cells.5
Current in vitro models for endothelial-tumor co-culture are achieved through either
overlaying an endothelial monolayer on top of matrix containing cancer cells14, 15 using
Transwell™ cell culture devices, or bringing the two types of cells into direct contact to form
co-spheroids.15 The former approach does not allow for real-time monitoring of both cell
types and their interactions because the membrane inserts are too distant from a microscope
objective16 and neither method preserves the normal morphological arrangement of the two
cell types. The use of co-spheroids measures morphological changes of the multi-cellular
structure, which is less quantitative, requires a longer term of culture and precludes the
ability to examine each cell type in its individually.
Microfluidic devices have been employed in a number of different cell culture applications,
with advantages in creating a precisely controlled geometrical, physical and biochemical
microenvironment for cells.17, 18 More recently, methods have been introduced to
incorporate multiple cell types in co-culture, simultaneous cell growth on 2-dimensional
(2D) surfaces and in 3-dimensional (3D) scaffolds, and control of a variety of biochemical
and biophysical factors while providing the capability for real-time imaging with standard
microscopy. These methods have been used to study, for example, cancer-endothelial cell
interactions,19 liver cell growth,20 biochemical gradient-guided cell growth,21, 22 and
migration,23 and to simulate certain aspects of organ function.24 While this technology
Aref et al. Page 2













shows promise in a variety of settings, it has not yet been used to examine EMT, and
requires further development before it can be applied to the quantitative assessment of
metastatic potential at the molecular and cellular level.
Here, we demonstrate a tumor microenvironment model based on a microfluidic device25
(Figs. 1A to 1C) capable of 1) recapitulating the physical and biochemical context that
allows for the manifestation of EMT of cancer cells in 3D, in the presence of human
endothelial cells; and 2) quantitatively monitoring the EMT inhibitory effect of drugs.
Cancer cell spheroids transferred to and grown in this device are induced to disperse in 3D
and exhibit mesenchymal morphology in a short timeframe, during co-culture with human
umbilical vein endothelial cells (HUVECs) without direct cell-cell contact (Fig. 1D). Drugs
that block specific signaling pathways introduced to the HUVEC-lined channel beside the
cancer spheroid-seeded collagen gel are shown to behave differentially in 3D than in 2D,
and interact strongly with the endothelial monolayer. These effects are shown to have a
significant effect on the concentration of drug needed to inhibit EMT.
Results
A549 lung adenocarcinoma cells were chosen for their ability to revert from an intermediate
mesenchymal-like phenotype to an epithelial-like phenotype with drugs known to interfere
with EMT pathways (data not shown). Their intermediate mesenchymal-like phenotype is
likely to result from an activated autocrine loop mediated by EGFR26 and TGF-βR1.27, 28
These cells respond to inhibitors of the EGFR signaling pathway including EGFR small
molecular weight inhibitors and antibodies to EGFR and to AZD 0530, a potent Src inhibitor
(Fig. S1A).29 A549 cells can also respond to A83-01, an ALK5/TGF-βR1 inhibitor (Fig.
S1B).27 An estimated IC50 for EMT reversal on monolayer culture was found to be 630 nM
for AZD 0530 and 2500 nM for A83-01 from analysis of phase contrast images.
A549 cells were then analyzed as spheroids under different experimental conditions to test
the role of the 2D and 3D environments. In the first experimental setting (2D culture), A549
spheroids were plated onto the surface of tissue culture dishes. Cells delaminating from
spheroids began to spread after 2 h of seeding, suggesting that the adhesive strength to the
substrate exceeded cell-cell adhesion. In control experiments, the cells continued to disperse
over a 24 h period (Fig. 2A). In contrast, spheroids treated with CI-1033, a clinically
relevant EGFR inhibitor, did not migrate from the base of the spheroid in contact with the
substrate (Fig. 2B). For Cl-1033, 50% inhibition concentration of cell dispersal was attained
at 5.2 μM in the 2D assay (Fig. 2C).
3D culture of A549 spheroids was achieved by suspending spheroids in the gel region of the
microfluidic system (Fig. 1) in the absence or presence of an endothelial cell monolayer. A
first series of experiments was conducted to determine the potential EMT-inducing activity
of the endothelial cell culture medium. Results demonstrated that A549 spheroids do not
dissociate within a 36 h period of incubation in the presence of the endothelial cell culture
medium alone (Fig. 3A) even though it contains fibroblast growth factor basic (FGF-B),
EGF, and recombinant-3 insulin-like growth factor-1 (R3-IGF1) and fetal bovine serum
(FBS). Spheroids do dissociate, however, in the presence of endothelial cells within 12 h
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(Fig. 3B) whereas dissociation is fully suppressed using the EGFR inhibitor CI-1033 at
300nM concentration (Fig. 3C). Confocal immunofluorescence microscopy demonstrated
that the increment of vimentin and loss of E-cadherin from the spheroids after co-culturing
with HUVECs for 36 h (Fig. 4).
Drugs interfering with EGFR, IGFR, PDGFR and TGF-βRI/ALK5-depentdent activation as
well as others acting upon intracellular kinases such as Src, MEK and AKT were tested at
different concentrations in the 3D assay in order to determine concentrations needed to
produce full inhibition of dispersion in a 36 h period of incubation (Table 1).
In order to investigate the effects of 2D vs. 3D microenvironments on spheroid dispersion,
parallel screening experiments were performed using conventional 2D microwells, and the
results, expressed in terms of the corresponding IC50 values, were determined. In every case
but one, the IC50 dose was considerably higher even than the dose required for full
inhibition in 3D (Table 1).
Normalized cell proliferation (N/N0) was used to evaluate cell growth and normalized cell
dispersion (Δ/Δ0) was used to evaluate cell migration away from the spheroid in the
presence of drugs. Twelve drugs were tested, each for at least two concentrations along with
one control (dose = 0; n = 12 devices) (Fig. 5). Time-dependent cell proliferation and
dispersion (Figs. 5A and 5C) indicated that the control condition exhibited the strongest
cancer cell activity in terms of both proliferation and dispersion. Compared with the control
condition, increasing drug dose caused a significant (p<0.05) decrease in cell proliferation as
well as a reduction in cell dispersion (Figs. 5B and 5D). By plotting normalized proliferation
against normalized dispersion of cancer spheroids at 36 h (Fig. 6), we are able to define four
quadrants to characterize the dose response for each drug. The upper right quadrant where
the control data points fall indicates cases with high rates of proliferation and dispersion.
Most drug-treated data lie in the lower left quadrant corresponding to low proliferation and
low dispersion activity. Therefore, it appears that for the conditions tested, whenever the
drug was effective in reducing cell dispersion, it also inhibited proliferation. At the higher
doses, the effects on proliferation were more marked.
Discussion
The primary purpose of this study was to examine the importance of a 3D microenvironment
and co-culture with an endothelial monolayer in the screening of potential drug targets to
inhibit EMT. Our rationale was that, as in numerous other biological processes, the nature of
the local environment and signaling from neighboring cell types would lead to significant
differences in how EMT of an epithelial cell line is manifested. Such differences can be
quantified by metrics used to assess the effect of drug on cell spreading and proliferation.
EMT provides a basis for understanding the progression of carcinoma towards
dedifferentiated and more malignant states. Most current information about cancer invasion,
however, is obtained by the study of cells on 2D surfaces. In reality, cells are physically
organized in 3D patterns surrounded by ECM and interacting with other cells in vivo and the
importance of these factors is now becoming widely recognized.30–33
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As a step toward replicating in vivo conditions, we developed and demonstrated a 3D
microfluidic assay, and accompanying imaging and analysis, to characterize the statistics of
anti-metastatic drug responses. Our data demonstrate both qualitative and quantitative
differences between 2D monolayers of A549 cells and experiments with A549 spheroids in
2D and 3D, and further differences depending on whether or not the tumor cells
communicate with a nearby endothelial monolayer. In the case of A83-01 (Fig. S1B), for
example, a TGF-βR inhibitor, the differences in effective dose between 2D and 3D culture in
the microfluidic system and in combination with endothelial cells were considerable, more
than three orders of magnitude (5 nM vs. 2.5 μM). Concentrations of the 12 drugs found to
be effective in inhibiting EMT all fall in the range of 1μM or less, suggesting that any of
these could be potential candidates for therapy.
The 2D dispersion assay differs considerably from the 3D assay in terms of the spheroid
response. For example, in the case of CI-1033, an EGFR inhibitor, the IC50 for inhibition of
cell dispersion fell by nearly a factor of 10 comparing 2D dispersion (Fig. 2C) to 3D
microfluidic co-culture (Fig. 3A). Furthermore, our data in 3D co-culture are in closer
agreement with plasma concentrations for CI-1033 reported to be effective in clinical trials
(~102 nM). 34, 35 Similar results were found with the remaining eleven drugs. Interestingly,
when the spheroids are fully suspended in gel, they remain intact without spreading during
the entire 36 h observation period, even in the absence of drug and in the presence of
endothelial cell growth medium.
It should be noted that cell migration utilizes different mechanisms depending on whether
the migration is on a 2D substrate or through a 3D matrix.36, 37 Spheroid migration on 2D
substrates was earlier described as a competition between cell-cell and cell-substrate
adhesion forces.38 Therefore, different substrates and different size spheroids would play a
major role in determining the tendency of the spheroid to disperse. In 3D environments,
however, the spheroid is encapsulated by matrix, where migration is not only influenced by
the balance of forces, but also by the secretion of matrix metalloproteinases (MMP) needed
for ECM remodeling. EMT, in part, is known to promote MMP secretion. Indeed, recent
study36 has demonstrated that there is little overlap between the signaling pathways used in
2D and 3D migration. In addition, cell-cell signaling plays a critical role, as demonstrated
here between the HUVEC monolayer and the tumor cells, and this signaling also likely to
differ between the 2D and 3D conditions. Therefore, our results suggest the importance of
more realistic in vitro screening methods in identifying drugs that might inhibit cell
dispersion in vivo. A change in the local environment, whether the cells are embedded in
collagen gel or in contact with a rigid surface, can significantly alter the concentration of
drug needed to inhibit the EMT response.
Rapid dissociation of the compact A549 spheroids when in communication with the
endothelial monolayer can be reversed by inhibitors of EGFR and TGF-βR suggesting that
endothelial cells produce EGF39 and TGF-β40 family members. It is well-established that
A549 can undergo extensive conversion to a mesenchymal-like morphology in response to
EGF and with TGF-β,27, 28 and that antibodies to EGFR can revert A549 cells to an
epithelial phenotype. Our collection of data further suggest that several pathways can be
activated by endothelial-derived growth factors, and therefore, that drugs could be designed
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that inhibit the kinases involved in activation of A549 cells towards metastasis. However,
we cannot exclude the possibility that our drug interferes with production or release of
EMT-inducing factors by endothelial cells.
Another objective of these studies was to demonstrate the feasibility of using a 3D
microfluidic co-culture system as a screening platform for drugs aimed at preventing EMT.
The 3D spheroid system in this microfluidic design offers a unique opportunity to screen
drugs for their ability to interfere with EMT. The optically transparent microfluidic system
not only reproduced the ECM and multi-type cell microenvironment essential for a tumor to
develop in vivo, but also provided a means for quantitative, automatic detection of cells and
measurement of indices reflecting EMT progression in a time-dependent manner.
Modifications to this system could allow for high throughput screening of new compounds
or combination therapies that maximize the inhibition of EMT while minimizing other
adverse off target effects. Other cell types in addition to endothelial cells could also be
added, either in the gel or the HUVEC-lined channel, to create a more realistic testing
environment. Variations on the present design could also address other steps in the
metastatic cascade such as local invasion and intravasation. Since few methods exist today
for screening drugs directed at reversing metastatic potential, systems such as this that
mimic aspects of the tumor microenvironment could prove extremely useful.
Materials and Methods
Generation of A549-H2B-mCherry stable cells
The human lung carcinoma cell line A549 was obtained from ATCC (CCL-185) and grown
in DMEM supplemented with 10% FBS. The plasmid pH2B_mCherry_IRES_puro2 was
obtained from Addgene (Addgene plasmid 21045).41 A549 cells grown to 50~70%
confluency were transfected with FuGENE 6 (Roche). Red fluorescence at the nuclei
indicated a positive transfection. After 48 h, transfected A549 cells were treated with
puromycin at a concentration of 2.5 μg/ml. Cells surviving puromycin selection were sorted
using fluorescence-activated cell sorting FACS-Aria cell sorter (BD Science, USA) to obtain
the most brightly fluorescent cells and were subsequently maintained in serial passages
under puromycin selection to generate stable H2B-mCherry expressing A549 cells.
Cell maintenance and preparation of tumor spheroids
Human lung adenocarcinoma A549 cells (ATCC, US) stably expressing histone H2B-
mCherry were cultured in T75 flasks (Nunclon Δ-Surface, NUNC, Denmark), and passaged
once the cells exceeded 80% confluence. Every two days the culture medium was
replenished with Dulbecco’s modified Eagle medium (Gibco/Invitrogen 12100, USA)
supplemented with 10% fetal bovine serum (Gibco/Invitrogen, USA), 1 μg/ml puromycin
(Sigma-Aldrich, St. Louis, MO, USA), 100 units/ml penicillin - 100 units/ml streptomycin
(1× pen-strep, Invitrogen). Human umbilical vein endothelial cells (HUVEC) (Lonza, Basel,
Switzerland) were maintained in microvascular endothelial growth media (Lonza
EGM-2MV, Basel, Switzerland), i.e., Endothelial Basal Media - 2 (EBM - 2) supplemented
with SingleQuots ® including 5%(25 ml per 500 ml bottle) FBS, 1× pen-strep and
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hydrocortisone 0.2 ml, hFGF-B, 0.2 ml; vascular endothelial growth factor (VEGF), 0.5 ml;
R3-IGF-1, 0.5 ml; ascorbic acid, 0.5 ml; heparin, 0.5 ml; hEGF, 0.5 ml; and GA-1000, 0.5
ml. Both cell lines were dissociated using 0.05% trypsin–ethylenedinitriletetraacetic acid
(trypsin–EDTA) (Sigma-Aldrich, St. Louis, MO, USA) at 37 °C in an incubator for 3 min
followed by medium – inhibition of enzymatic reaction and single cells in suspension were
counted with a hemocytometer. We have herein prepared two different types of EGM-2MV,
one with VEGF and the other without. The one with VEGF was used to maintain the
HUVEC culture, while the other one is applied in seeding HUVEC in the devices, to prevent
unwanted exogenous VEGF degradation of collagen gel.
To generate spheroids, A549 cells were trypsinized and resuspended as individual cells at
2~4k cells/ml in DMEM,42 and seeded onto a 100 mm ultra-low attachment dish (Corning
Inc, NY, USA). These cells were cultured for 10–14 d and collected upon spheroid
formation (visible under microscopy and >40 μm). In our experiments, individual spheroids
were sieved via 100 μm and 40 μm cell strainers to yield spheroids 40–70 μm in diameter,
and centrifuged to separate them from the supernatant.
Microfluidic Device Design
The microfluidic tissue culture devices used in this study are described in detail by Farahat
et al.25 The devices (Fig. 1) consist of 2 media channels running parallel to and located on
either side of an extended central region containing the extracellular gel matrix, all formed
by bonding a coverslip to a patterned polydimethylsiloxane (PDMS) substrate. By varying
the composition of the growth media in the channels, drugs, growth factors or other agents
can be introduced, either at uniform concentration or as a gradient across the gel region, to
elicit cellular responses. Spheroid or individual cell behavior can be observed via 3D
confocal imaging of the gel region through the supporting glass coverslip.
Device Fabrication and Cell Seeding in 3D Matrix
The devices were fabricated in PDMS (Dow Corning® Sylgard 184) at a ratio of 10:1
polymer to cross-linker using standard soft lithography techniques.43 Devices were
autoclaved in DI water for 20 min followed by a dry autoclave cycle for 20 min and baked
overnight at 80°C to dry. Glass cover slips (#1.5 Cell Path, UK) were then plasma bonded to
the PDMS substrate that had been pretreated with ethanol and dried. All device channels
were then treated with 1 mg/ml poly-D-lysine (PDL) solution (Sigma-Aldrich, USA) for 4 h
to enhance cell and collagen matrix binding to PDMS,33 followed by another round of
drying at 80°C for 24–48 h to make the devices hydrophobic.
200 μl collagen gel solution at 2.5 mg/ml and pH 7.4 was prepared on ice with 126.1 μl type
I collagen (3.87 mg/ml, BD Biosciences Cat. No. 354236), 20 μl PBS (10x) with phenol red
(Gibco/Invitrogen 14080-055, USA), 43.1 μl deionized water, 7 μl NaOH (0.5N), and 20 μl
cell suspension medium with 30–50 tumor spheroids.44 The specific gel composition was
decided upon through a set of preliminary experiments in which we sought a balance
between rapid matrix degradation by endothelial cells for low collagen concentrations and
impaired cancer cell migration at high concentrations. Spheroid-containing collagen gel
solution was then pipetted into the central gel region at low pressure to avoid spillage into
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the side channels. Gel is confined to the central gel cage by means of surface tension. Once
in place, collagen gel solution was kept in a humidity box in at 37°C for 40 min to allow gel
polymerization via thermal cross-linking. DMEM and EGM-2MV with HUVECs were
subsequently introduced to respective media channels. After 1–2 h, HUVECs attached in
endothelial cell growth channel and formed a semi-confluent monolayer on the coverslip
bottom substrate and onto the gel surface. The conditioned medium produced by HUVEC
secretions diffuses into the adjacent collagen gel. Average distance between the HUVEC
and tumor spheroids was ~200 μm, facilitating rapid cell-cell signaling.
Immunofluorescent staining
Cell culture media was removed from the devices and samples in the microfluidic devices
were first rinsed in cold PBS and then fixed in 4% PFA (Sigma-Aldrich, St. Louis, MO,
USA) for 15 min at room temperature. Then 0.1% Triton-X (Sigma-Aldrich, St. Louis, MO,
USA) was added and incubated for 5 min before blocking by Block Ace (Dainippon
Phamaceutical, Osaka, Japan) for 2 h. To demonstrate the endothelial cell monolayer
formation, staining of VE-cadherin (1:100, mouse; Sigma Aldrich, USA) was carried out.
For analysis of epithelial marker expression, E-cadherin (1:100, mouse; Sigma Aldrich,
USA) was used to stain for cell-cell junctions; and nuclei were stained with DAPI (Sigma-
Aldrich, USA). Fluorescent images were obtained using FluoView 1000 confocal
microscopy (Olympus, Japan). The secondary antibody used was 2mg/ml Alexa Fluor 488-
conjugated anti-mouse IgG antibodies (Invitrogen, USA). For analysis of vimentin
expression, vimentin (1:200, rabbit; Invitrogen, USA) was used and incubated again with 2
mg/ml Alexa Fluor 488-conjugated anti-rabbit IgG antibodies (Invitrogen, USA), and DNA
was labeled by Hoechst (Invitrogen, USA). Fluorescent images were obtained using a phase-
contrast microscope equipped for fluorescence (Nikon, Japan).
2D Drug Screening
Twelve kinase inhibitors acting on different targets were selected (Table 1), based on a
preliminary screen showing their inhibitory potential on A549 EMT reversal in 2D culture at
2.5 μM concentration (Fig. S1). A549 cells were grown in 96-well plates on 2D from a
sparse density of 800 cells/cm2 and cultured in the presence of concentration of 0.04, 0.16,
0.63, 2.5, 10μM. Cells were imaged after 72 h incubation using IX51 with 10x objective
(Olympus, Japan).
2D dispersion assay achieved by culturing spheroids in tissue culture dishes was also studied
over 24 h (Fig. 2). Spheroids were seeded in a 96-well plate (Falcon, USA) with ~10–20 per
well. Spheroids were supplemented with DMEM medium, and for a range of CI-1033
concentrations: 10, 50, 100, 500, 1,000, 5,000, 10,000, 50,000, and 100,000 nM. For the
remaining eleven drugs, concentrations of 5, 50, 500, 5,000, and 50,000 nM were used. IC50
of each drugs were summarized (Table 1).
3D Drug Screening
An appropriate range of concentrations to study was identified through an initial series of
experiments in the microfluidic device under 3D conditions. Some of these compounds are
approved by the U.S. Food and Drug Administration (FDA) or are currently being used in
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clinical trials for the treatment of lung cancer (e.g. Gefitinib and AZD 0530). As noted in
Table 1, some of these compounds primarily block receptor activation while others act
intracellularly to inhibit specific signaling pathways known to be activated during EMT.
Drugs were mixed with both cancer and endothelial cell media, and applied in both
channels.
Image Acquisition and Analysis
Three dimensional image stacks of each studied spheroid were acquired using FluoView
1000 confocal microscopy (Olympus, Japan) with a 10X objective (NA = 0.4). Three image
channels were acquired for each stack: GFP, mCherry, and transmitted light. Each imaging
volume encompassed a 1272.32 micron by 1272.32 micron region allowing simultaneous
observation of endothelial cell channel and spheroids. The volumetric Z-stack covered a
range of ~160 μm over 18–20 slices per stack. Images were acquired at 0, 12 and 36 h.
From the spatial coordinates of the centroids of all nuclei determined through the process of
segmentation, de-noising, and edge-enhancement (see Supplemental Information), we first
compute the spheroid center, xs, then the standard deviation of nuclei from the spheroid
center,
which is termed the “dispersion” both in 2D dispersion assay and in 3D microfluidic co-
culture of a spheroid. Two metrics are used to assess drug efficacy: normalized dispersion,
Δ/Δ0, and normalized cell number (N/N0) where the normalizing values (Δ0 and N0) are the
values at t=0.
The “effective dose” in 3D microfluidic co-culture was determined as the lowest tested
concentration deemed sufficient to prevent dispersion (Table 1), i.e., the concentration at
which Δ/Δ0 at t=36 h < 1.42. In cases for which IC50 values of 2D dispersion assay are
reported, its determination is based on a curve-fit to the data for at least 5 different
concentrations of a particular drug with a minimum of 3 repeats for each condition.
Conclusion
EMT provides a new basis for understanding the progression of carcinoma towards
dedifferentiated and more malignant states. However, most of the current information about
cancer invasion is obtained by the study of tumor cells acting by themselves in a non-
physiologic environment on 2D surfaces. In reality, cells are physically organized in vivo in
3D patterns surrounded by ECM as well as other cell types. As a step toward a more realistic
in vitro assay, we developed and demonstrated a 3D microfluidic system, and accompanying
image analysis process to characterize the statistics of anti-metastatic drug responses.
Results confirm the importance of growing cells in 2D vs. 3D and that other cell types, in
this case endothelial cells, can significantly alter the levels of drug required to inhibit EMT.
These studies therefore offer a new approach in drug screening with the potential to better
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replicate the in vivo microenvironment. They also offer the prospect of including other cell
types and matrices to produce even greater realism with tissue-specific characteristics in
future studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Schematic and photograph of 3D co-culture microfluidic device. A. Schematic diagram of
device layout depicts the inlets for injecting cells, filling collagen, and replenishing medium.
B. Enlarged view of gel region and HUVEC-lined channel. Cytokines in conditioned
medium from HUVEC monolayer diffuse into the gel region triggering spheroids to undergo
EMT. C. Photograph of the PDMS-molded device bonded on a glass cover-slip. D. A 3D co-
culture image combining phase contrast and fluorescence with enlarged HUVECs
monolayer structure and 3D cancer spheroid dispersion. Blue: Hoechst; green: VE-Cadherin;
red: nuclei mCherry.
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Dispersion measurements of A549 spheroids in 2D conditions in a 96-well plate. A.
Spheroids were seeded in wells in control medium and allow to spread. B. Treatment with
10 μM CI-1033, an EGFR inhibitor, reduced the dissociation of cancer cells from spheroids.
C. 50% inhibition concentration of CI-1033 was achieved at 5,200 nM.
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Fluorescent images in time-series showing A549 cell dissemination in the 3D collagen gel.
A. Control condition in the absence of a HUVEC monolayer, i.e., 3D monoculture. B.
Control condition in the presence of a HUVEC monolayer in the side channel, i.e. 3D co-
culture. C. EGF-targeted drug (300nM of CI-1033) applied in the presence of HUVEC
monolayer. Red: nuclei of A549 cells; green: HUVEC. Triangles show the PDMS posts on
the edge of collagen gel.
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Immunostaining of EMT markers on A549 spheroids at 0 h and 36 h in co-culture with
HUVECs. A–D. Expression of vimentin in spheroids at 0 h and 36 h. Blue: nuclei; green:
vimentin. E–H. Expression of E-cadherin in spheroids at 0 h and 36 h. Blue: nuclei; green:
E-cadherin.
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Analysis of cell dispersion and proliferation in the presence or absence of drug treatment. A.
Normalized dispersion for twelve drugs. B. Representative normalized dispersion measured
over time for three concentrations of AZD 0530. C. Normalized proliferation for twelve
drugs. D. Representative normalized proliferation measured over time for three
concentrations of AZD 0530. The values for the effective dose for full inhibition are given
in Table 1.
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Normalized cell dispersion and corresponding cell number at 36 h. Four quadrants were
defined to characterize the dose response for each drug. The \upper right quadrant indicates
cases with high rates of proliferation and dispersion, where we find the control conditions.
Most drug-treated data lie in the lower left quadrant with low proliferation and low
dispersion activity. Therefore, it appears that for the conditions tested, drugs reduced cell
dispersion and cell proliferation simultaneously.
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